Supriya Lifescience Ltd (BOM:543434) (Q1 2027) Earnings Call Highlights: Revenue Surges 31% to ...

• EBITDA declined 8.1% year-on-year to INR47 crores, with margins at 25%, impacted by temporary cost headwinds.

• Water shortages due to delayed monsoon led to a deferment of sales of around INR35 crores.

• Changes in Maharashtra's solar power policy increased fuel and power costs, impacting EBITDA by INR8 crores.

• PAT declined to INR24 crores from INR35 crores in Q1 FY26, with PAT margin at 12.7%.

• The launch of the contrast media product has been delayed by two quarters due to R&D fine-tuning and raw material cost variations.

• A customs issue related to a psychotropic drug export remains sub judice, with a general manager in judicial custody.

• Inventory levels are on the higher side at INR230-240 crores, which will need to be liquidated over the next few quarters.

• The revenue mix from backward-integrated products declined, impacting EBITDA margins.

• The Patalganga facility is still in early stages, with only boundary wall construction started and API block expected to take around 2.5 years for 40% completion.

• The company faces potential tariff risks in North America, though current exposure is limited.

Q & A Highlights

Q: Can you provide more color on the higher costs related to water and power for Q2, and reconfirm the annual guidance for revenue and EBITDA margins? A: Saloni Wagh (Managing Director) confirmed that the water issue is resolved and will not recur in Q2. The power cost impact was largely retrospective and will not repeat. Operational price increases will be passed on to customers. The company remains confident in achieving its guidance of closer to INR1,000 crores in revenue while maintaining EBITDA margins between 32% to 35% for FY27.

Q: What is the status of the Patalganga land development, and what is the timeline for the Phase 1 CapEx of INR200 crores? A: Krishna Raghunathan (CFO) stated that ground has been broken with boundary wall construction underway. The first focus will be on the API block, with a target of 40% completion within 2.5 years from acquisition. Saloni Wagh (MD) added that Patalganga will be crucial for scaling up larger molecules as Lote capacity nears exhaustion, with finished formulations deferred to Phase 2.

Q: What is the status of the EU audit for the Ambernath facility, and when can we expect revenue generation from regulated markets? A: Saloni Wagh (MD) confirmed that the EU audit dates have been received and are scheduled for the second half of November. This audit is a key trigger for ramping up product sales in regulated markets like Europe.

Q: What is the status of the contrast media product launch, and how are you managing the challenge of obtaining specifications from the few formulators in the market? A: Saloni Wagh (MD) explained that the launch has been delayed by two quarters due to R&D fine-tuning the technology to be cost-competitive. The strategy involves a combination of API for non-regulated markets and finished formulation tie-ups for regulated markets. The value addition will come from a better, more cost-effective process.

Q: Can you provide an update on the CMO/CDMO contracts and the progress of the large anesthetic contract? A: Saloni Wagh (MD) stated that significant progress has been made on a large anesthetic CDMO contract, and they are very close to signing a term sheet. Qualification work is complete, and quality has been approved. An announcement is expected in the next quarter.

Q: What is the status of the DSM ramp-up, and has the pharma validation been completed? A: Saloni Wagh (MD) confirmed that the DSM project has reached a very stable state, close to peak volumes. Pharma validation is completed, and a dedicated facility for DSM is now up and running.

Q: What is the status of the customs issue, and has a provision been made against the booked sales? A: Saloni Wagh (MD) clarified that the matter is sub judice, but a new export authorization has been received from the Central Bureau of Narcotics, which should regularize the export. Krishna Raghunathan (CFO) added that no provision has been made as the issue is expected to be resolved amicably. The incident was a 2-day technical lapse in the export authorization, limited to a single consignment.

Q: What is the expected depreciation for the full year, including the Ambernath facility? A: Krishna Raghunathan (CFO) stated that Ambernath alone would contribute around INR14-15 crores in depreciation. The overall depreciation for the company is expected to be in the range of INR35-40 crores.

Q: What is the status of the planned maintenance shutdown in Q2, and what is its impact on revenue? A: Saloni Wagh (MD) stated that the planned large shutdown has been pushed back to avoid further production impact. Instead, smaller debottlenecking activities will be undertaken across different blocks to minimize any major impact on Q2 production.

Q: What is the company's plan to sustain growth beyond FY27, and is there any guidance for FY28? A: Saloni Wagh (MD) reiterated the 20% CAGR growth target. Beyond FY27, the company is working on multiple fronts: adding new products and therapies, expanding the finished formulation vertical at Ambernath, entering CMO/CDMO collaborations, and investing in the Patalganga facility for capacity building. These initiatives are expected to drive growth over the next 3-4 years.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .